Table 3.

Minimal duration of treatment before obtaining a significant risk reduction for a) vertebral fractures; b) hip fractures and c) non-vertebral fractures according to the included studies. (*p < 0.05, **p < 0.01, ***p < 0.001, NS – not significant, NA - not analysed).

a) For vertebral fractures
	Before 12 months	After 12 months
Oral bisphosphonates (Black et al., 2000; Chesnut et al., 2004; Harris et al., 1999; Liberman et al., 1995): Alendronate Risedronate Ibandronate	NS	*** ** **
Zoledronate (Dennis et al., 2007)	***	***
Denosumab (Steven et al., 2007; Boonen et al., 2011)	***	***
Teriparatide (Body et al., 2020; Lindsay et al., 2009)	**	**
Abaloparatide (Cosman et al., 2017; Miller et al., 2016a)	NA	***
Romosozumab (Cosman et al., 2016; Saag et al., 2017)	**	**

b) For non-vertebral fractures
	Before 12 months	After 12 months
Oral bisphosphonates (Black et al., 2000; Harris et al., 1999; Liberman et al., 1995): Alendronate Risedronate	NS	* *
Zoledronate (Dennis et al., 2007)	***	***
Denosumab (Steven et al., 2007)	*	*
Teriparatide (Body et al., 2020)	**	**
Abaloparatide (Cosman et al., 2017; Miller et al., 2016a)	*	*
Romosozumab (Cosman et al., 2016; Saag et al., 2017)	NS	*

c) For hip fractures
	Before 12 months	After 12 months
Oral bisphosphonates (Black et al., 2000; Liberman et al., 1995): Alendronate	NS	*
Zoledronate (Dennis et al., 2007)	***	***
Denosumab (Steven et al., 2007; Boonen et al., 2011)	*	*
Teriparatide (Eriksen et al., 2014; Lindsay et al., 2009)	*	*
Romosozumab (Saag et al., 2017)	NS	*